Compare Abbott Laboratories (ABT) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Select Medical Holdings Corporation — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Abbott Laboratories is far larger — about 81.4× Select Medical Holdings Corporation's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SEM | |
|---|---|---|
Market Cap | $166.94B | $2.05B |
Sector | Health | Health |
52-Week High | $136.62 | $16.66 |
52-Week Low | $82.57 | $11.77 |
Enterprise Value | $193.69B | $5.01B |
Dividend Yield | 2.63% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, with a bullish technical signal supported by oversold RSI readings. The company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43 and P/S of 0.36 indicating reasonable valuation. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share, finalized on June 30, 2026.
The acquisition at $16.50 per share, just below the current price, limits near-term upside, while ongoing legal investigations into the board's fiduciary duties pose governance risks. Analyst consensus is mixed with 35.71% buy ratings, but stagnant revenue and declining net income margins signal fundamental challenges. Investors should weigh the acquisition's finality against operational headwinds and shareholder litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
